Medical/Pharmaceuticals
Lumonus Announces Transformative Multi-Year Licensing Agreement with Smarter Radiation Oncology® to bring evidenced-based directives to U.S. cancer centers
NEW YORK and SYDNEY, Sept. 29, 2025 /PRNewswire/ -- Lumonus
2025-09-30 00:00
1371
Smartee Chief Scientist Prof. Gang Shen Recognized Among World's Top 2% Scientists for Orthodontic Contributions
SHANGHAI, Sept. 29, 2025 /PRNewswire/ -- Smartee Denti-Technology today announced that Professor Gang Shen, its Chief Scientist and Executive President of TaiKang ByBo Dental, has once again been named to theWorld's Top 2% Scientistslist, compiled by Stanford University in partnership with Elsevi...
2025-09-29 17:56
1303
Hanmi's Oral Delivery Platform Compound Licensed to Gilead
Hanmi and HHP will grant Gilead an exclusive license to Encequidar and provide access to drug supply. SEOUL, South Korea, Sept. 29, 2025 /PRNewswire/ -- Hanmi Pharm announced on September 29 that it has entered into a global licensing and collaboration agreement with Gilead Sciences, Inc. ("Gile...
2025-09-29 17:45
1402
Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry
Viva Biotech is acknowledged for its pioneering AI-driven drug discovery platforms that accelerate timelines, reduce costs, and expand therapeutic innovation in the global pharmaceutical R&D ecosystem. SHANGHAI, Sept. 29, 2025 /PRNewswire/ -- Viva Biotech announced today that it has been honored...
2025-09-29 17:00
1252
International Health Experts: China's Experience Benefits Global Health Governance
BEIJING, Sept. 28, 2025 /PRNewswire/ -- A news report from Xinhua Finance, "Over the past few years, we have seenChina gradually increase its universal health coverage, boost investment, and place great emphasis on preventive medicine. While advancing its 'Healthy China 2030' initiative,China has...
2025-09-28 20:50
1517
The 2025 BPD Singapore Conference Has Concluded Successfully! Jointly Embarking on a New Journey for Global Development
SINGAPORE, Sept. 26, 2025 /PRNewswire/ -- The 2025 BPD (Biopharmaceutical Bioprocess Development) Singapore Summit, which co-hosted by WuXi XDC (Stock Code: 2268.HK), was successfully concluded fromSeptember 24-26, 2025. The conference brought together leading biopharmaceutical companies and rese...
2025-09-27 10:45
3768
Datasea Reports Record Fiscal Year 2025 Revenue of $71.62 Million, Up 199% Year-over-Year
DTSS Achieves Fourth Quarter Net Income Breakeven Driven by Cutting-Edge Acoustics and AI Multimodal Digitalization; Ongoing Commercialization Updates in the Coming Weeks BEIJING, Sept. 26, 2025 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada-based high-tech ente...
2025-09-26 21:30
5467
Concord Medical Reports Financial Results for the First Half of 2025
BEIJING, Sept. 26, 2025 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced its unaudited consolidated financial results for t...
2025-09-26 19:30
3444
Jacobio Chairman and Concerted Parties Increase Shareholding by Nearly HK$100 Million, Demonstrating Confidence in Long-term Growth
BEIJING, SHANGHAI and BOSTON, Sept. 25, 2025 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK)today announced that its Chairman and Chief Executive Officer, Dr. Yinxiang Wang, together with concerted parties, have recently increased their shareholding in the Company by 11.06 million shares, repr...
2025-09-26 08:47
1899
Bambusa Therapeutics Announces Highly Positive Healthy Volunteer Results and First Atopic Dermatitis Patient Dosed in Phase I Trial of BBT001
BOSTON, Sept. 25, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa Therapeutics), a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology and inflammation, today announced two landmark achievements for its lead program, BBT001. Last week, Ba...
2025-09-25 22:04
1933
The FDA Granted Orphan Drug Designation to Biostar Pharma's Utidelone for the Treatment of Pancreatic Cancer
SAN FRANCISCO, Sept. 25, 2025 /PRNewswire/ -- Biostar Pharma, Inc., the US wholly-owned subsidiary of Beijing Biostar Biopharmaceutical Co., Ltd. ("Biostar," stock code: 2563.HK) which is a synthetic biology driven biopharma company focusing on the discovery, development and commercialization of ...
2025-09-25 21:37
2237
Flat Medical Establishes Clinical Advisory Board for Pain Interventions, Names Dr. Krishnan Chakravarthy as Chairman
AUSTIN, Texas, Sept. 25, 2025 /PRNewswire/ -- Flat Medical, a leading innovator in medical device solutions, today announced the formation of itsClinical Advisory Board for Chronic Pain Interventions and the appointment of Dr. Krishnan Chakravarthy, MD, PhD, as its inaugural Chairman. This strate...
2025-09-25 21:00
1727
WuXi Biologics Launches WuXia™4.0, Targeted Integration Cell Line Platform TrueSite TI™，to Accelerate Biologics Development with High Titer and Superior Stability
* TrueSite TI™, the fourth generation of WuXia™ cell line platform, leverages targeted integration technique to streamline clone screening and guarantees expression stability. * The platform has achieved an average mAb titer exceeding 8.0 g/L with over 99% of clonal cell lines maintaining sta...
2025-09-25 19:42
1906
Lunit, CellCarta Announce Global Alliance to Expand Access to Digital Pathology AI for Clinical Trials
SEOUL, South Korea and MONTREAL, Sept. 24, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and biomarkers for oncology therapeutics, today announced a strategic partnership with CellCarta, a globally recognized provider of CRO laboratory services for p...
2025-09-24 21:00
2227
GCCL and Frontage Laboratories Announce Strategic Collaboration to Strengthen Global Clinical Trial Capabilities
YONGIN, South Korea, Sept. 24, 2025 /PRNewswire/ -- GCCL (Global Clinical Central Lab), aSouth Korea-based leading provider of clinical trial sample analysis, and Frontage Laboratories, Inc., aUSA based full-service contract research organization (CRO), announced on September 23 that they had sig...
2025-09-24 13:29
1924
Noul Secures FDA Registration for Cervical Cancer Diagnostic Cartridge
* FDA registration fulfills requirements for U.S. market entry * Initial shipments to Europe and Latin America to begin with pre-approved countries YONGIN, South Korea, Sept. 23, 2025 /PRNewswire/ -- Noul Co., Ltd. (CEO:David Lim), a medical AI company specializing in blood and cancer diagnos...
2025-09-23 21:00
1523
HKeyBio Lauched the Most Comprehesive Non-human Primate Autoimmune & Allergic Disease Model Matrix to Redefining Clinical Translation
BOSTON and SUZHOU, China, Sept. 23, 2025 /PRNewswire/ -- HKeyBio, a CRO specializing in preclinical and translational autoimmune-drug development, today announced the launch ofHKEY-NHP-MATRIX2.0, a next-generation platform designed to improve the reliability of translating novel autoimmune and al...
2025-09-23 20:35
1867
Mindray Unveils Project 2030 and Re-writes the Future of Women's Health Ultrasound at ISUOG
CANCUN, Mexico, Sept. 23, 2025 /PRNewswire/ -- On September 15th, at ISUOG 2025 World Congress inCancun, Mexico, Mindray unveiled Project 2030, an initiative to improve global access to ultrasound technology. The project was launched to an international audience of leading specialists, capping a ...
2025-09-23 13:48
1337
GC Biopharma Submits IND Application for Phase 1 Clinical Trial of COVID-19 mRNA Vaccine in Korea
YONGIN, South Korea, Sept. 22, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a leading South Korean pharmaceutical company, announced today that it has submitted an Investigational New Drug (IND) application to the Ministry of Food and Drug Safety (MFDS) inSouth Korea for a Phase 1 clinical tria...
2025-09-23 09:41
1707
Galux Demonstrates De Novo Antibody Design With Structural and Functional Validation Across Eight Targets
* Study confirms the novelty and atomic-level precision of de novo antibody design, including cryo-EM validation on a designed anti-PD-L1 antibody * Findings highlight broad therapeutic applicability across oncology, immune, and metabolic diseases SEOUL, South Korea, Sept. 22, 2025 /PRNewswire...
2025-09-22 21:00
1932
Week's Top Stories
Most Reposted
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 328 media titles]
2026-02-19 14:30
NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 310 media titles]
2026-02-23 08:00
Vitafoods Asia 2026 Expands by 30%: A Bigger, More Dynamic Trade Event with Exciting New Features & Increased International Participation
[Picked up by 289 media titles]
2026-02-23 10:09
Little Artists Art Studio, Singapore Shines at Art Capital 2026
[Picked up by 280 media titles]
2026-02-17 19:12
Kung Fu Meets Spring -- Unitree Spring Festival Gala Robots Present "Cyber Real Kung Fu" in the Year of the Horse
[Picked up by 259 media titles]
2026-02-17 14:16